tirzepatide day 3 3: Mounjaro (Tirzepatide – weekly injection) Class: Dual GLP-1 and GIP receptor agonist Avg Weight Loss: ~20% of baseline weight (SURMOUNT-1 trial) FDA Status: Approved for type 2 diabetes; Fast-tracked for Unexpected Benefits from My First

Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence

doi: 10.1055/s-0042-101794 [DOI] [PubMed] [Google Scholar] 82

Kolovrat M, Gojkovic S, Krezic I, Malekinusic D, Vrdoljak B, Kasnik Kovac K, et al

DPP-4 inhibitors: Linagliptin: hepatobiliary excretion (no dose adjustment required in patients with renal impairment, making it preferred) Other DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, and alogliptin) are predominantly eliminated by the kidneys, so dosage must be adjusted in cases of severe renal dysfunction

They are best thought of as a hydration support tool , not a treatment plan

Growth Des